Open AccessA phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors
Author(s) -
Tracy Murray-Stewart,
Apurva A. Desai,
Michael L. Fitzgerald,
Laurence J. Marton,
Robert A. Casero
Publication year - 2020
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-020-04082-4
Subject(s) - maximum tolerated dose , solid tumor , medicine , phase (matter) , polyamine , oncology , cancer research , chemistry , chemotherapy , cancer , biochemistry , organic chemistry
Polyamines are essential for the sustained proliferation and biomass required by tumor cells. Bis-alkylated polyamine analogs are nonfunctional competitors of natural polyamines. Of these, PG-11047, a second-generation unsaturated analog of the polyamine spermine, has demonstrated anticancer activity in cell lines and animal models of multiple cancer types. This report describes the first phase I clinical trial to investigate PG-11047 in patients with advanced refractory metastatic solid tumors.